Month: August 2025

– Definitive asset purchase agreement for 11 MW Bitcoin mining site in Mississippi– Direct mining margin improved to 41.0% from 38.5% in Q1 2025– $0.1 million GAAP net income and $2.6M Core EBITDA, up from sequential $5.4 million net loss and $2.8 million negative Core EBITDA in Q1 2025, respectively– Held 150.4 Bitcoin on July 31, 2025 valued at approximately $18.0 million, as of August 11, 2025 TAMPA, Fla., Aug. 14, 2025 (GLOBE NEWSWIRE) — LM Funding America, Inc. (NASDAQ: LMFA) (“LM Funding” or the “Company”), a Bitcoin mining and technology-based specialty finance company, today reported financial results for the three months ended June 30, 2025. Q2’25 Financial HighlightsTotal revenue for the quarter was $1.9 million dollars, down 18.7% sequentially from Q1 2025 and down 36.0% year-over-year. The...

Q2 Revenue of $11.8 Million, an Increase of 14% over Q2 2024 50% Growth in Revenue for International Medical Cannabis International Medical sales now 57% of Total Revenue Cash Balance of $10.4 Million at the end of Q2, Increased from $8.4 Million in Q1 2025 Management to Host Conference Call / Webcast on August 14th, 2025 at 10:00 am ETTORONTO, Aug. 14, 2025 (GLOBE NEWSWIRE) — MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm”, “MediPharm Labs” or the “Company”), a pharmaceutical company specialized in precision-based cannabinoids, today announced its financial results for the three and six months ended June 30, 2025. MediPharm achieved strong year-over-year revenue growth in Q2 2025 and continued to advance its international medical cannabis strategy, supported by a...

Announced updated Phase 2 data at ASCO for vilastobart, a tumor-activated, Fc-enhanced, anti-CTLA-4, demonstrating deep and durable responses and a meaningfully differentiated safety and tolerability profile for an anti-CTLA-4 combination therapy On track with plans to nominate first development candidates for wholly owned masked T cell engager programs in second half of 2025 $121.6 million in cash and cash equivalents as of June 30, 2025, with anticipated cash runway through end of third quarter of 2026 WALTHAM, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) — Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced pipeline progress and business updates and reported financial results for the second...

–        Revenue of $5.2 million–        Gross margin of 33%–        Adjusted EBITDA margin of 3%–        Awarded three new projects HOUSTON, Aug. 14, 2025 (GLOBE NEWSWIRE) — Koil Energy Solutions, Inc. (OTCQB: KLNG), a specialist in deepwater energy production and distribution equipment and services, released today its second quarter 2025 results and announced three new projects. “After a modest first half of 2025, momentum is building. Today, we announced three new projects, and recent weeks have brought a sharp rise in service activity and robust order intake on fixed‑price contracts,” said Erik Wiik, President and Chief Executive Officer of KOIL Energy. “These are clear indicators of strengthening demand heading into the second half of the year.” Second Quarter 2025 Results: For the three months ending...

Q2 2025 Net Product Sales Increased 47% Year-over-Year to $3.8 Million SOLANA BEACH, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) — Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders with an emphasis on GIMOTI® (metoclopramide) nasal spray, today reported financial results for the second quarter ended June 30, 2025, and provided a business update. “This quarter’s results demonstrate the commercial strength of GIMOTI and the precision of our execution,” said Matt D’Onofrio, Chief Executive Officer of Evoke Pharma. “With 47% year-over-year growth in net product sales and a 20% increase in new prescribers since the second quarter of last year, demand is accelerating from both physicians and patients. Fill rates are improving, and prescriber adoption is broadening...

PITTSBURGH, Aug. 14, 2025 (GLOBE NEWSWIRE) — Predictive Oncology (Nasdaq: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, and CLIA laboratory to accelerate oncologic drug discovery and enable drug development, today reported financial and operating results for the quarter ended June 30, 2025, and provided a corporate update. The Company reported a loss from continuing operations of approximately $2.0 million. Q2 2025 and Recent Highlights:Continued to advance preparations for an aggressive market expansion of ChemoFx®, its validated flagship live cell drug response assay, in the U.S. and de novo Launch in Europe.By testing multiple chemotherapies on a patients’ cancer cells before treatment selection, ChemoFx helps...

Advancing novel programs for respiratory viruses that pose pandemic threats or risk of serious illness, including SARS CoV2 (ratutrelvir) and influenza (Tivoxavir marboxil, TXM) Prioritization of ratutrelvir, a ritonavir-free, protease inhibitor regimen in development for Acute and Long COVID, reflects the ongoing infection risk and greater need, with waning vaccine utilization A submitted HREC study will enable initiation of Phase 2 studies of ratutrelvir in newly diagnosed COVID patients, with extensions to assess rebound and Long COVID, as well as evaluation in PAXLOVID®-ineligible subjects TXM program to emphasize focus on stockpiling readiness Traws to host a Q2 2025 business update call today, August 14th at 8:30 AM ET NEWTOWN, Pa., Aug. 14, 2025 (GLOBE NEWSWIRE) — Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws”...

NEW YORK, Aug. 14, 2025 (GLOBE NEWSWIRE) — Chicago Atlantic BDC, Inc. (“LIEN” or the “Company”) (NASDAQ: LIEN), a specialty finance company that has elected to be regulated as a business development company, today announced its financial results for the second quarter ended June 30, 2025. Second Quarter 2025 Highlights and Subsequent ActivityTotal gross investment income of $13.1 million Net investment income of $7.7 million, or $0.34 per weighted average share outstanding Total investment portfolio of $307.5 million at fair value Net asset value (“NAV”) per share was $13.23 on June 30, 2025 Declared a dividend of $0.34 per share for the quarter ending September 30, 2025 payable on October 10, 2025 to shareholders of record of September 29, 2025 Funded nine portfolio companies with $39.1 million in aggregate par value during...

VALUE Phase III Trial of EscharEx® in Venous Leg Ulcers Continues to Enroll Patients NexoBrid® Manufacturing Expansion on Track; Full Operational Capacity Expected by Year-End 2025 Additional Strategic Research Collaborations Established with Essity and Convatec Second Quarter 2025 Revenue of $5.7 Million, Up 43% from Prior Quarter Conference Call Today, August 14, 2025, at 8:30am Eastern Time YAVNE, Israel, Aug. 14, 2025 (GLOBE NEWSWIRE) — MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced financial results for the second quarter ended June 30, 2025, and provided a corporate update. “We continue to execute across our clinical, commercial, and operational objectives,” said Ofer Gonen, Chief Executive Officer of MediWound. “The VALUE Phase III trial of EscharEx®...

Revenues of $3.5 million, Weaker Gross Margin, and Net Loss MISSISSAUGA, Ontario, Aug. 14, 2025 (GLOBE NEWSWIRE) — Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, reports results for its third quarter and nine months of fiscal 2025 ended June 30, 2025 (“Q3” and “YTD”). Sales for Q3 were down for both Antigens and QAPs™, while YTD Antigens were up and QAPs were down YTD. Management DiscussionResults for Q3 were disappointing, impacted by two key events, cancellation of test-development programs by a key customer and the decline in sales to China. YTD recurring revenues of $14.4 million are slightly lower than prior year. Financial strength remains, with strong cash & equivalents and overall liquidity. New business development is proceeding well but...